Accelerating discovery of liver disease mechanisms
Google DeepMind ● Covered by 3 sources
A biomedical team at the University of Edinburgh used an AI system called Co-Scientist to identify overlooked biological connections in metabolic dysfunction-associated steatohepatitis (MASH), a liver disease involving multiple intertwined processes. The AI synthesised evidence across liver biology and pharmacology to propose that the NLRP3 inflammasome links inflammation and metabolism in MASH, a connection that had not previously been integrated into a single explanation. This hypothesis, later experimentally verified, could enable the development of targeted combination therapies for patients who do not respond to existing single-target drugs like resmetirom.
Why it matters
Filippo Menolascina uses Co-Scientist to identify new liver disease treatments and explain why existing drugs only help certain patients.
